# Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

> **NCT00005970** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3436 (actual)

## Conditions studied

- Breast Adenocarcinoma
- HER2 Positive Breast Carcinoma
- Stage IA Breast Cancer AJCC v7
- Stage IB Breast Cancer AJCC v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7

## Interventions

- **DRUG:** Aromatase Inhibition Therapy
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **DRUG:** Tamoxifen Citrate
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT00005970
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05-19
- **Primary completion:** 2005-04-25
- **Final completion:** 2010-01-27
- **Target enrollment:** 3436 (ACTUAL)
- **Last updated:** 2020-08-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005970, "Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00005970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*